2019 Q1 Form 10-Q Financial Statement
#000156459019019236 Filed on May 15, 2019
Income Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| Revenue | $8.629M | $5.793M |
| YoY Change | 48.96% | -60.98% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $7.720M | $4.410M |
| YoY Change | 75.06% | |
| % of Gross Profit | ||
| Research & Development | $15.18M | $13.08M |
| YoY Change | 16.04% | |
| % of Gross Profit | ||
| Depreciation & Amortization | $1.137M | $1.162M |
| YoY Change | -2.15% | |
| % of Gross Profit | ||
| Operating Expenses | $22.90M | $17.50M |
| YoY Change | 30.86% | |
| Operating Profit | -$14.27M | -$11.70M |
| YoY Change | 21.9% | |
| Interest Expense | $20.00K | -$340.0K |
| YoY Change | -105.88% | |
| % of Operating Profit | ||
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | -$14.25M | -$12.05M |
| YoY Change | 18.26% | |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$14.25M | -$12.05M |
| YoY Change | 18.3% | 981.33% |
| Net Earnings / Revenue | -165.14% | -207.94% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$623.1K | -$543.8K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 22.93M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $170.6M | |
| YoY Change | ||
| Cash & Equivalents | $26.62M | $6.632M |
| Short-Term Investments | $144.0M | |
| Other Short-Term Assets | $2.600M | |
| YoY Change | ||
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $3.300M | |
| Other Receivables | $0.00 | |
| Total Short-Term Assets | $176.5M | |
| YoY Change | ||
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $9.900M | |
| YoY Change | ||
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $13.70M | |
| YoY Change | ||
| Other Assets | $2.235M | |
| YoY Change | ||
| Total Long-Term Assets | $25.96M | |
| YoY Change | ||
| TOTAL ASSETS | ||
| Total Short-Term Assets | $176.5M | |
| Total Long-Term Assets | $25.96M | |
| Total Assets | $202.5M | |
| YoY Change | ||
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.395M | |
| YoY Change | ||
| Accrued Expenses | $2.502M | |
| YoY Change | ||
| Deferred Revenue | $19.02M | |
| YoY Change | ||
| Short-Term Debt | $0.00 | |
| YoY Change | ||
| Long-Term Debt Due | $5.800M | |
| YoY Change | ||
| Total Short-Term Liabilities | $31.13M | |
| YoY Change | ||
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $8.500M | |
| YoY Change | ||
| Other Long-Term Liabilities | $32.10M | |
| YoY Change | ||
| Total Long-Term Liabilities | $40.60M | |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $31.13M | |
| Total Long-Term Liabilities | $40.60M | |
| Total Liabilities | $71.70M | |
| YoY Change | ||
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$154.3M | |
| YoY Change | ||
| Common Stock | $284.9M | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $130.7M | -$120.7M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $202.5M | |
| YoY Change |
Cashflow Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$14.25M | -$12.05M |
| YoY Change | 18.3% | 981.33% |
| Depreciation, Depletion And Amortization | $1.137M | $1.162M |
| YoY Change | -2.15% | |
| Cash From Operating Activities | -$20.15M | -$15.01M |
| YoY Change | 34.21% | |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $276.0K | $364.0K |
| YoY Change | -24.18% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$77.80M | $0.00 |
| YoY Change | ||
| Cash From Investing Activities | -$78.08M | -$364.0K |
| YoY Change | 21350.27% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -458.0K | -14.00K |
| YoY Change | 3171.43% | |
| NET CHANGE | ||
| Cash From Operating Activities | -20.15M | -15.01M |
| Cash From Investing Activities | -78.08M | -364.0K |
| Cash From Financing Activities | -458.0K | -14.00K |
| Net Change In Cash | -98.68M | -15.39M |
| YoY Change | 541.29% | |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$20.15M | -$15.01M |
| Capital Expenditures | $276.0K | $364.0K |
| Free Cash Flow | -$20.42M | -$15.37M |
| YoY Change | 32.83% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
21574000 | |
| CY2019Q1 | us-gaap |
Debt Current
DebtCurrent
|
5766000 | |
| CY2018Q4 | us-gaap |
Debt Current
DebtCurrent
|
4724000 | |
| CY2019Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
443000 | |
| CY2018Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
847000 | |
| CY2019Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
31130000 | |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
36423000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
31520000 | |
| CY2018Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
44599000 | |
| CY2019Q1 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
469000 | |
| CY2018Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
476000 | |
| CY2018Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
10000000 | |
| CY2018Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
102000 | |
| CY2019Q1 | us-gaap |
Assets
Assets
|
202458000 | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2244000 | |
| CY2019Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
15000 | |
| CY2018Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
15000 | |
| CY2018Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
79194000 | |
| CY2018Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
2489000 | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2965000 | |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
209946000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
10934000 | |
| CY2019Q1 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
13747000 | |
| CY2019Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2235000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
223139000 | |
| CY2019Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3395000 | |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3061000 | |
| CY2019Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2502000 | |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6217000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
19024000 | |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
184421000 | |
| CY2019Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22925441 | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
91600000 | |
| CY2019Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
23000 | |
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
23000 | |
| CY2019Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
284890000 | |
| CY2018Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
281891000 | |
| CY2019Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
56000 | |
| CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-47000 | |
| CY2019Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-154251000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
130718000 | |
| CY2019Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
202458000 | |
| CY2019Q1 | us-gaap |
Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
|
1188000 | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22848184 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22925441 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22848184 | |
| CY2019Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
8629000 | |
| CY2018Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
5793000 | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15180000 | |
| CY2018Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
13082000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7715000 | |
| CY2018Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4414000 | |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
22895000 | |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
17496000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14266000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11703000 | |
| CY2019Q1 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
1176000 | |
| CY2018Q1 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
40000 | |
| CY2019Q1 | stro |
Interest And Other Expense Net
InterestAndOtherExpenseNet
|
1160000 | |
| CY2018Q1 | stro |
Interest And Other Expense Net
InterestAndOtherExpenseNet
|
383000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14250000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12046000 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.62 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-25.75 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
22865075 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
467719 | |
| CY2019Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
4916000 | |
| CY2018Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
4084000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
103000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
0 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-14147000 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-12046000 | |
| CY2019Q1 | stro |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
42000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
671000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2286000 | |
| CY2019Q1 | us-gaap |
Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
|
10327000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-109001000 | |
| CY2018Q1 | stro |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
38000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
249000 | |
| CY2018Q1 | stro |
Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Shares
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfShares
|
14000 | |
| CY2018Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-120746000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-14250000 | |
| CY2018Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-12046000 | |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1137000 | |
| CY2018Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1162000 | |
| CY2019Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
600000 | |
| CY2018Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
0 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2286000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
264000 | |
| CY2019Q1 | stro |
Reduction Of The Liability Attributable To A Research Development And Commercialization Agreement
ReductionOfTheLiabilityAttributableToAResearchDevelopmentAndCommercializationAgreement
|
127000 | |
| CY2018Q1 | stro |
Reduction Of The Liability Attributable To A Research Development And Commercialization Agreement
ReductionOfTheLiabilityAttributableToAResearchDevelopmentAndCommercializationAgreement
|
0 | |
| CY2019Q1 | us-gaap |
Accretion Expense
AccretionExpense
|
42000 | |
| CY2018Q1 | us-gaap |
Accretion Expense
AccretionExpense
|
38000 | |
| CY2019Q1 | stro |
Revaluation Of Option Liability
RevaluationOfOptionLiability
|
14000 | |
| CY2018Q1 | stro |
Revaluation Of Option Liability
RevaluationOfOptionLiability
|
0 | |
| CY2019Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-17000 | |
| CY2018Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-35000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2531000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
849000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
276000 | |
| CY2019Q1 | stro |
Deferred Initial Public Offering Costs Included In Accounts Payable
DeferredInitialPublicOfferingCostsIncludedInAccountsPayable
|
0 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-336000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
130000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
476000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-189000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-3715000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
980000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
397000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
44000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
7000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
-21000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-5302000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-2658000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-20145000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-15010000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
119053000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
0 | |
| CY2019Q1 | stro |
Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
|
37750000 | |
| CY2018Q1 | stro |
Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
|
0 | |
| CY2019Q1 | stro |
Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
|
3500000 | |
| CY2018Q1 | stro |
Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
|
0 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
364000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-78079000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-364000 | |
| CY2019Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
0 | |
| CY2018Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
52000 | |
| CY2019Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
500000 | |
| CY2018Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
0 | |
| CY2019Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
42000 | |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
38000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-458000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-14000 | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-98682000 | |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-15388000 | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value Including Discontinued Operations
CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
|
125313000 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value Including Discontinued Operations
CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
|
22035000 | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value Including Discontinued Operations
CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
|
26631000 | |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value Including Discontinued Operations
CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
|
6647000 | |
| CY2019Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
330000 | |
| CY2018Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
300000 | |
| CY2019Q1 | stro |
Vesting Of Early Exercised Shares
VestingOfEarlyExercisedShares
|
0 | |
| CY2018Q1 | stro |
Vesting Of Early Exercised Shares
VestingOfEarlyExercisedShares
|
14000 | |
| CY2019Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
63000 | |
| CY2018Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
5000 | |
| CY2018Q1 | stro |
Deferred Initial Public Offering Costs Included In Accounts Payable
DeferredInitialPublicOfferingCostsIncludedInAccountsPayable
|
53000 | |
| CY2019Q1 | stro |
Embedded Interest Associated With Program Fees
EmbeddedInterestAssociatedWithProgramFees
|
860000 | |
| CY2018Q1 | stro |
Embedded Interest Associated With Program Fees
EmbeddedInterestAssociatedWithProgramFees
|
0 | |
| CY2019Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and Principal Activities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sutro Biopharma, Inc. (the “Company”) is a clinical stage drug discovery, development and manufacturing company focused on leveraging its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+™, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders. The Company was incorporated on April 21, 2003, and was formerly known as Fundamental Applied Biology, Inc. The Company is headquartered in South San Francisco, California. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one business segment, the development of biopharmaceutical products. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidity </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred significant losses and has negative cash flows from operations. As of March 31, 2019, there was an accumulated deficit of $154.3 million. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities and costs to operate as a public company. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019, the Company had unrestricted cash, cash equivalents and marketable securities of $184.3 million, which are available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and its operations. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its unrestricted cash, cash equivalents and marketable securities as of March 31, 2019 will be sufficient for the Company to continue as a going concern for at least one year from the issuance date of its unaudited interim condensed financial statements. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> | |
| CY2018Q4 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
2489000 | |
| CY2019Q1 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2003-04-21 | |
| CY2019Q1 | dei |
Entity Incorporation State Country Name
EntityIncorporationStateCountryName
|
South San Francisco, California | |
| CY2019Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2019Q1 | stro |
Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value
UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue
|
184300000 | |
| CY2019Q1 | us-gaap |
Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
|
false | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
46116 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
60000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q1 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-1160000 | |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
6632000 | |
| CY2018Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
15000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
6647000 | |
| CY2019Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
184365000 | |
| CY2019Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
56000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
195443000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
47000 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
195396000 | |
| CY2019Q1 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
19000000 | |
| CY2019Q1 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P12M | |
| CY2019Q1 | stro |
Convertible Preferred Stock Warrant Liability Fair Value
ConvertiblePreferredStockWarrantLiabilityFairValue
|
100000 | |
| CY2018Q4 | stro |
Convertible Preferred Stock Warrant Liability Fair Value
ConvertiblePreferredStockWarrantLiabilityFairValue
|
100000 | |
| CY2019Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
400000 | |
| CY2018Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
400000 | |
| CY2019Q1 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
one vote per share | |
| CY2019Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
7543257 | |
| CY2018Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
6250381 | |
| CY2019Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.5800 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.7289 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.7489 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0240 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0272 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0255 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0273 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.86 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
8.39 | |
| CY2019Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
1700000 | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
200000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2286 | |
| CY2018Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
249 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
210000 | |
| CY2018 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
210000 | |
| CY2019Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14250000 | |
| CY2018Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-12046000 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4411627 | |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5978905 |
